Toronto, ON, (January 14, 2010) -Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel* (etanercept) in the treatment of ...

STELARA Recommended for Approval in Paediatric Patients 12 Years and Older with Moderate to Severe Psoriasis Beerse, Belgium, 22 May 2015 - Janssen-Cilag International NV ("Janssen") announced today ...

Janssen announced new data from the Phase 3 study, IM-UNITI, showing that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving maintenance treatment ...

Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA ...

Johnson & JohnsonJNJ announced new data from a phase III study, evaluating its drug Stelara in adults with moderate-to-severe ulcerative colitis ("UC"). The eight-week induction data from the pivotal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. HONOLULU — In the UNITI-2 clinical trial, researchers ...

Johnson & Johnson JNJ announced new data from a phase III study, evaluating its drug Stelara in adults with moderate-to-severe ulcerative colitis (“UC”). The eight-week induction data from the pivotal ...

A final pooled safety analysis of six Phase 2/3 IBD studies included 2,575 patients treated with STELARA and a total of 4,826 patient-years (PY) of follow-up. "These long-term studies underscore ...

STELARA is licensed for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant to other systemic therapies including ...

The FINANCIAL — Phase 3 data presented for the first time showed treatment with STELARA (ustekinumab) induced clinical response and clinical remission in patients with moderate to severe Crohn’s ...